Northland Securities upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a market perform rating to an outperform rating in a research report released on Monday morning, The Fly reports.
Separately, Zacks Investment Research raised vTv Therapeutics from a hold rating to a buy rating and set a $3.00 price target on the stock in a research report on Tuesday, January 22nd.
Shares of vTv Therapeutics stock opened at $1.51 on Monday. The firm has a market capitalization of $69.29 million, a PE ratio of -2.19 and a beta of -3.79. vTv Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $6.09.
vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.92 million during the quarter. Analysts forecast that vTv Therapeutics will post -0.54 EPS for the current year.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 815,217 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The shares were purchased at an average cost of $1.84 per share, with a total value of $1,499,999.28. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.70% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Wedbush Securities Inc. bought a new stake in shares of vTv Therapeutics during the 1st quarter worth about $30,000. Barclays PLC boosted its stake in shares of vTv Therapeutics by 366.7% during the 4th quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 22,000 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new stake in shares of vTv Therapeutics during the 4th quarter worth about $186,000. 1.16% of the stock is currently owned by hedge funds and other institutional investors.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Further Reading: What causes a recession?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.